ArticleCancers2021

Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer.

Gabriela Silva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.